Drug profile · INN
crovalimab
PIASKY
crovalimab (PIASKY) is a complement c5 inhibitor.
EMA: approved PMDA: approved Antineoplastic and immunomodulating agents (L04) L04AJ07
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — crovalimab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.83
Quick answer
crovalimab (PIASKY) is a complement c5 inhibitor.
Key facts
INN crovalimab
Brand PIASKY
Mechanism Complement C5 inhibitor
Target Complement C5
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AJ07
Mechanism of action
Complement C5 inhibitor
Primary target: Complement C5
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is crovalimab?
crovalimab (PIASKY) is a complement c5 inhibitor.
What is the brand name for crovalimab?
PIASKY is a marketed brand name for crovalimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.